Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus

Turiel, 2005, Cardiac imaging techniques in systemic autoimmune diseases, Lupus, 14, 727, 10.1191/0961203305lu2209oa

Story, 1994, A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to the fetus, J Exp Med, 180, 2377, 10.1084/jem.180.6.2377

Buyon, 1998, Autoimmune associated congenital heart block: mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry, J Am Coll Cardiol, 31, 1658, 10.1016/S0735-1097(98)00161-2

Buyon, 2003, Neonatal lupus: review of proposed pathogenesis and clinical data from the US-based research registry for neonatal lupus, Autoimmunity, 36, 41, 10.1080/0891693031000067340

Cooley, 1997, Monozygotic twins discordant for congenital complete heart block, Arthritis Rheum, 40, 381, 10.1002/art.1780400223

Saleeb, 1999, Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibodies-associated congenital heart block: retrospective review of the research registry for neonatal lupus, Arthritis Rheum, 42, 2335, 10.1002/1529-0131(199911)42:11<2335::AID-ANR12>3.0.CO;2-3

Askanase, 2002, Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies, Lupus, 11, 145, 10.1191/0961203302lu173oa

Brucato, 1995, Isolated congenital complete heart block: longterm outcome of children and immunogenetic study, J Rheumatol, 22, 541

Kertesz, 1997, Congenital complete atrioventricular block, Tex Heart Inst J, 24, 301

Moak, 2001, Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela, J Am Coll Cardiol, 37, 238, 10.1016/S0735-1097(00)01048-2

Nield, 2002, Maternal anti-Ro and anti-La antibody associated endocardial fibroelastosis, Circulation, 105, 843, 10.1161/hc0702.104182

Brucato, 2001, Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women, Arthritis Rheum, 44, 1832, 10.1002/1529-0131(200108)44:8<1832::AID-ART320>3.0.CO;2-C

Julkunen, 2001, The rate of recurrence of isolated congenital heart block: a population based study, Arthritis Rheum, 44, 487, 10.1002/1529-0131(200102)44:2<487::AID-ANR70>3.0.CO;2-D

Buyon, 2004, Neonatal lupus syndromes, Lupus, 13, 705, 10.1191/0961203304lu2008oa

Glickstein, 2000, Pulsed Doppler echocardiographic assessment of the fetal PR interval, Am J Cardiol, 86, 236, 10.1016/S0002-9149(00)00867-5

Blandfort, 1977, In vitro metabolism of prednisolone, dexamethasone, betametasone and cortisol by the human placenta, Am J Obstet Gynecol, 127, 264, 10.1016/0002-9378(77)90466-5

Jaeggi, 2004, Transplacental fetal treatment improves the outcome of prenatally complete atrioventricular block without structural heart disease, Circulation, 110, 1542, 10.1161/01.CIR.0000142046.58632.3A

Baud, 2001, Neurotoxic effects of fluorinated glucocorticoids preparations on the developing mouse brain: role of preservatives, Pediatr Res, 50, 706, 10.1203/00006450-200112000-00013

Spinillo, 2004, Two years infant neurodevelopment outcome after single or multiple antenatal courses of corticosteroidi to prevent complications of prematurity, Am J Obstet Gynecol, 191, 217, 10.1016/j.ajog.2003.12.023

Brucato, 2006, Normal neuropsycological development of children with congenital heart block exposed or not in utero to high dose of dexamethasone, Ann Rheum Dis, 10.1136/ard.2005.049866

Costedoat-Chalumeau, 2003, Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block, Ann Rheum Dis, 62, 1010, 10.1136/ard.62.10.1010

Sonesson, 2004, Signs of first degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52 Kd antibodies, Arthritis Rheum, 50, 1253, 10.1002/art.20126

Costedoat-Chalumeau, 2004, Outcome of pregnancy in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiografic variations in the children and comparison with a control group, Arthritis Rheum, 50, 3187, 10.1002/art.20554

Costedoat-Chalumeau, 2005, Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and treatment options, Arthritis Res Ther, 7, 69, 10.1186/ar1690

D'Cruz, 2001, Cardiovascular manifestations of systemic lupus erythematosus, Dubois' lupus erythematosus, 645

Doria, 2005, Cardiovascular involvement in systemic lupus erythemathosus, Lupus, 14, 683, 10.1191/0961203305lu2200oa

Doria, 2004, Cardiac involvement in systemic lupus erythematosus, The heart in systemic autoimmune disease, 146

Kow, 2002, How to manage patients with cardiopulmonary disease?, Best Pract Res Clin Rheumatol, 16, 211, 10.1053/berh.2001.0222

Brigden, 1960, The heart in systemic lupus erythematosus, Br Heart J, 22, 1, 10.1136/hrt.22.1.1

Godeau, 1981, Manifestations cardiques du lupus erythemateaux aigu dissemine, Nouv Presse Med, 10, 2175

Leung, 1990, Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross-sectional and Doppler echocardiographic study, Int J Cardiol, 27, 367, 10.1016/0167-5273(90)90294-F

Bulkley, 1975, The heart in systemic lupus erythemathosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients, Am J Med, 58, 243, 10.1016/0002-9343(75)90575-6

Logar, 1990, Possible association between anti Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythemathosus, Ann Rheum Dis, 49, 627, 10.1136/ard.49.8.627

Berg, 1985, Systemic lupus erythematosus presenting as an isolated congestive heart failure, J Rheumatol, 12, 1182

Singh, 2005, Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report, Lupus, 14, 137, 10.1191/0961203305lu2050oa

Sherer, 1999, Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus, Clin Rheumatol, 18, 238, 10.1007/s100670050091

Chung, 2005, Giant cell myocarditis: a rare cardiovascular manifestation in a patient with systemic lupus erythematosus, Lupus, 14, 166, 10.1191/0961203305lu2040cr

Libman, 1924, A hitherto undescribed form of valvular and mural endocarditis, Arch Int Med, 33, 701, 10.1001/archinte.1924.00110300044002

Cervera, 2002, Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis Rheum, 46, 1019, 10.1002/art.10187

Hojnik, 1996, Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome, Circulation, 93, 1579, 10.1161/01.CIR.93.8.1579

Turiel, 2000, Evaluation of cardiac abnormality and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography, Lupus, 9, 406, 10.1191/096120300678828532

Erdogan, 2005, Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study, Stroke, 36, 592, 10.1161/01.STR.0000154858.27353.df

Krause, 2005, Close association between valvular disease and central nervous system manifestations in antiphospholipid syndrome, Ann Rheum Dis, 64, 1490, 10.1136/ard.2004.032813

Salmon, 2001, Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management, Curr Opin Rheumatol, 13, 341, 10.1097/00002281-200109000-00001

Van Doornum, 2002, Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthtritis?, Arthritis Rheum, 46, 862, 10.1002/art.10089

Doria, 2005, Inflammation and accelerated atherosclerosis: basic mechanisms, Rheum Dis Clin N Am, 31, 355, 10.1016/j.rdc.2005.01.006

Petri, 2001, Systemic lupus erythematosus: clinical aspects, Arthritis and allied conditions, 14th, 1455

Shoenfeld, 2005, Accelerated atherosclerosis in autoimmune rheumatic diseases, Circulation, 112, 3337, 10.1161/CIRCULATIONAHA.104.507996

Sherer, 2006, Mechanisms of disease: atherosclerosis in autoimmune diseases, Nat Clin Pract Rheumatol, 2, 1, 10.1038/ncprheum0092

Rhew, 2006, Premature atherosclerotic disease in systemic lupus erythematosus – role of inflammatory mechanisms, Autoimmun Rev, 5, 101, 10.1016/j.autrev.2005.08.008

Bruce, 2005, Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?, Best Pract Res Clin Rheumatol, 19, 823, 10.1016/j.berh.2005.05.001

Urowitz, 1976, The bimodal mortality pattern of systemic lupus erythematosus, Am J Med, 60, 221, 10.1016/0002-9343(76)90431-9

Bulkley, 1975, The heart in SLE and the changes induced in it by corticosteroid therapy, Am J Med, 53, 243, 10.1016/0002-9343(75)90575-6

Manzi, 1997, Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus, Am J Epidemiol, 145, 408, 10.1093/oxfordjournals.aje.a009122

Cervera, 1999, Morbidity and mortality in systemic lupus erythematosus during a 5 year period: a multicenter prospective study of 1000 patients, Medicine, 78, 167, 10.1097/00005792-199905000-00003

Petri, 1992, Coronary artery disease risk factors in the Johns Hopkins lupus cohort: prevalence, recognition by patients and preventive practice, Medicine, 71, 291, 10.1097/00005792-199209000-00004

Petri, 1992, Risk factors for coronary artery disease in patients with systemic lupus erythematosus, Am J Med, 93, 513, 10.1016/0002-9343(92)90578-Y

Doria, 2004, Premature coronary disease in systemic lupus, N Eng J Med, 350, 1571, 10.1056/NEJM200404083501518

George, 1999, The involvement of beta2-glycoprotein I in human and murine atherosclerosis, J Autoimmun, 13, 57, 10.1006/jaut.1999.0288

Delgado Alves, 2002, Antibodies to high density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome, Arthritis Rheum, 46, 2686, 10.1002/art.10542

Maatsura, 2002, Autoantibodies-mediated atherosclerosis, Autoimmun Rev, 1, 348, 10.1016/S1568-9972(02)00084-8

George, 2001, Accelerated intimal thickening in carotid arteries of balloon-injured rats after immunization against shock protein 70, J Am Coll Cardiol, 38, 1564, 10.1016/S0735-1097(01)01579-0

George, 2004, Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2- glycoprotein I, Cardiovasc Res, 62, 603, 10.1016/j.cardiores.2004.01.028

Veres, 2004, Antiphospholipid antibodies in acute coronary syndrome, Lupus, 13, 423, 10.1191/0961203304lu1011oa

Petri, 2004, The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort, Thromb Res, 114, 593, 10.1016/j.thromres.2004.07.012

Ranzolin, 2004, Anti-beta2-glycoprotein I antibodies as risk factors foe acute myocardial infarction, Arq Bras Cardiol, 83, 141

Toloza, 2004, Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events, Arthritis Rheum, 50, 3947, 10.1002/art.20622

Baron, 2005, Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome, Ann Rheum Dis, 64, 144, 10.1136/ard.2003.016204

Roman, 2003, Prevalence and correlates of accellerated atherosclerosis in systemic lupus erythematosus, N Engl J Med, 349, 2399, 10.1056/NEJMoa035471

Doria, 2003, Risk factors for subclinical atherosclerosisin a prospective cohorts of patients with systemic lupus erythemathosus, Ann Rheum Dis, 62, 1071, 10.1136/ard.62.11.1071

Soltész, Endothelial dysfunction, early and accelerated atherosclerosis in systemic autoimmune diseases, Orv Hetil (Hung Med J)

Jimenez, 2005, Preclinical vascular disease in systemic lupus erythemathosus and primary antiphospholipid syndrome, Rheumatology, 44, 756, 10.1093/rheumatology/keh581

Lockshin, 2003, Cardiac disease in the antiphospholipid syndrome: recommendations for treatment, Lupus, 12, 518, 10.1191/0961203303lu391oa

Jury, 2005, Statins: immunomodulators for autoimmune rheumatic disease?, Lupus, 14, 192, 10.1191/0961203303lu2135oa

Wahl, 2000, Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks?, Arch Int Med, 160, 2042, 10.1001/archinte.160.13.2042

Leung, 2002, Mortality and malignancy in the multi-ethnic Birmingham Lupus Cohort - aspirin use is beneficial and non-Caucasian origin is not associated with a poor outcome, Rheumatology, 41, S17

2004, Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus – proposed guidelines for risk factor management, Rheumatology, 43, 7, 10.1093/rheumatology/keg436

Khamashta, 1995, The management of thrombosis in the antiphospholipid antibody syndrome, N Engl J Med, 332, 993, 10.1056/NEJM199504133321504